Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl intranasal spray - Kyowa Kirin International

Drug Profile

Fentanyl intranasal spray - Kyowa Kirin International

Alternative Names: Fentanyl; Fentanyl pectin; Fentanyl pectin nasal spray; FPNS; Lazanda; Nasalfent; PecFent

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator West Pharmaceutical Services
  • Developer AstraZeneca; Kyowa Kirin International; ProStrakan
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain
  • No development reported Anaesthesia

Most Recent Events

  • 28 May 2019 No recent reports of development identified for phase-I development in Anaesthesia(Adjuvant therapy) in USA (Intranasal, Spray)
  • 01 Mar 2018 Fentanyl intranasal spray is licensed to Slan Medicinal Holdings in Canada and USA
  • 07 Nov 2017 Depomed enters into agreement to divest fentanyl intranasal spray to Slan Medicinal Holdings
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top